Comparative evaluation of subtyping tools for surveillance of newly emerging HIV-1 strains by L. Fabeni et al.
Comparative Evaluation of Subtyping
Tools for Surveillance of Newly
Emerging HIV-1 Strains
Lavinia Fabeni,a Giulia Berno,a Joseph Fokam,b Ada Bertoli,c Claudia Alteri,c
Caterina Gori,a Federica Forbici,a Desiré Takou,b Alessandra Vergori,a
Mauro Zaccarelli,a Gaetano Maffongelli,d Vanni Borghi,e Alessandra Latini,f
Alfredo Pennica,g Claudio Maria Mastroianni,h Francesco Montella,i
Cristina Mussini,e Massimo Andreoni,d Andrea Antinori,a Carlo Federico Perno,a
Maria Mercedes Santoro,c The Resistance Study Group
National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italya; Chantal Biya International
Reference for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroonb; University of Rome
Tor Vergata, Rome, Italyc; University Hospital Tor Vergata, Rome, Italyd; Modena University Hospital, Modena,
Italye; San Gallicano Dermatological Institute, IRCCS, Rome, Italyf; S. Andrea Hospital, Rome, Italyg; Polo Pontino-
Sapienza University, Latina, Italyh; S. Giovanni Addolorata Hospital, Rome, Italyi
ABSTRACT HIV-1 non-B subtypes/circulating recombinant forms (CRFs) are increas-
ing worldwide. Since subtype identiﬁcation can be clinically relevant, we assessed
the added value in HIV-1 subtyping using updated molecular phylogeny (Mphy) and
the performance of routinely used automated tools. Updated Mphy (2015 updated
reference sequences), used as a gold standard, was performed to subtype 13,116
HIV-1 protease/reverse transcriptase sequences and then compared with previous Mphy
(reference sequences until 2014) and with COMET, REGA, SCUEAL, and Stanford subtyp-
ing tools. Updated Mphy classiﬁed subtype B as the most prevalent (73.4%), followed by
CRF02_AG (7.9%), C (4.6%), F1 (3.4%), A1 (2.2%), G (1.6%), CRF12_BF (1.2%), and other
subtypes (5.7%). A 2.3% proportion of sequences were reassigned as different subtypes
or CRFs because of misclassiﬁcation by previous Mphy. Overall, the tool most concor-
dant with updated Mphy was Stanford-v8.1 (95.4%), followed by COMET (93.8%),
REGA-v3 (92.5%), Stanford-old (91.1%), and SCUEAL (85.9%). All the tools had a high
sensitivity (98.0%) and speciﬁcity (95.7%) for subtype B. Regarding non-B subtypes,
Stanford-v8.1 was the best tool for C, D, and F subtypes and for CRFs 01, 02, 06, 11, and
36 (sensitivity, 92.6%; speciﬁcity, 99.1%). A1 and G subtypes were better classiﬁed by
COMET (92.3%) and REGA-v3 (98.6%), respectively. Our ﬁndings conﬁrm Mphy as the
gold standard for accurate HIV-1 subtyping, although Stanford-v8.1, occasionally com-
bined with COMET or REGA-v3, represents an effective subtyping approach in clinical
settings. Periodic updating of HIV-1 reference sequences is fundamental to improving
subtype characterization in the context of an effective epidemiological surveillance of
non-B strains.
KEYWORDS HIV-1, subtypes, circulating recombinant forms, phylogeny, subtyping
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Human immunodeﬁciency virus type 1 (HIV-1) is characterized by extensive geneticdiversity due to various mechanisms driven by its evolution within an infected
individual, thus leading to a broad viral heterogeneity (1–3).
HIV-1 has been divided into four groups: M, O, N, and P (1, 3, 4). The HIV-1 pandemic
has been mainly caused by group M (1–3, 5), which is subdivided into 9 subtypes (A to
D, F to H, J, and K) and at least 79 circulating recombinant forms (CRFs) (http://www
.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html, accessed 25 February 2017) and
multiple unique recombinant forms (URFs) widely spread across the globe.
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The dominant HIV-1 strain in North America, Western Europe, and Australia is
subtype B. As a result, the great majority of HIV-1 clinical research has been conducted
in populations where subtype B predominates. However, this subtype represents only
11% of global HIV-1 infections (6). Of note, among non-B strains, subtypes A, C, and F
and CRFs 01_AE and 02_AG are responsible for over 70% of all infections, and there are
increasing trends of non-B subtypes and newly emerging CRFs reported in the Western
world (7–11), including Italy (12, 13).
Geographical patterns in subtype distribution are changing over time, due to
migration and the mixing of populations (9).
In addition to the epidemiological impact, the spread of HIV-1 subtypes is clinically
relevant: HIV-1 clades show differences in pathogenesis and resistance pathways, with
implications for clinical outcomes, diagnosis, viral quantiﬁcation, and vaccine develop-
ment (14–19). With continuous discovery of new HIV-1 strains (https://www.hiv.lanl
.gov/content/sequence/HIV/CRFs/CRFs.html) coupled with the increasing phylogeog-
raphy and phylodynamics of non-B subtypes spreading into Western countries (6–8; see
also WHO data at http://www.who.int/gho/hiv/en/), it would be of paramount impor-
tance to accurately identify newly emerging strains, both for efﬁcient molecular epi-
demiological surveillance and for optimal clinical management of patients infected
with diverse HIV-1 strains, particularly in Italy, where the migration rate is high (12, 13).
Proper detection and description of clinical HIV-1 samples remain challenging,
particularly in the frame of increasing recombinant forms (CRFs and URFs), since
algorithms are designed mainly for the B strains (20–22).
Practically, HIV-1 subtyping can be performed through several approaches, among
which automated tools are commonly used for clinical purposes (23–25), while molec-
ular phylogeny (Mphy) is commonly used for epidemiological surveillance. To date,
Mphy is the gold standard for both epidemiological surveillance and clinical practice
(23). However, this gold standard is not widely used in routine practice due to its
complexity (it is manually performed, cumbersome, and time-consuming and requires
skills in data interpretation). In addition, Mphy might not be updated regularly with
reference sequences.
Routine subtyping is often based on automated tools because they are user friendly,
speedy, and free of charge (24, 26). However, they have considerable limitations
compared to Mphy especially in assigning non-B variants: outputs of different tools are
usually in disagreement (26–28), their algorithms are not regularly updated, and they
have only a limited number of CRFs in the reference data set. In routine clinical practice,
the most commonly used automated tools are statistically based use of partial match-
ing compression algorithms (context-based modeling for expeditious typing [COMET]
(29), a similarity-based tool (Stanford HIV drug resistance database [Stanford]), and
phylogenetics-based tools (REGA and subtype classiﬁcation using evolutionary algo-
rithms [SCUEAL]).
We thus aimed at assessing the added value of updated Mphy (using recently
available HIV-1 reference sequences) and determining the performance of four com-
monly used automated subtyping tools (COMET, Stanford, REGA, and SCUEAL) against
updated Mphy, in order to propose a highly reliable approach for subtyping in routine
clinical practice.
(This work was presented in part as a poster at the VIIIth Italian Conference on AIDS
and Antiviral Research Workshop, 6 to 8 June 2016, Milan, Italy [30].)
RESULTS
Mphy subtype assignment. Of the total 13,116 HIV-1 pol sequences analyzed and
based on new Mphy, B was the most prevalent subtype (73.4%), followed by CRF02_AG
(7.9%), C (4.6%), F1 (3.4%), A1 (2.2%), G (1.6%), CRF12_BF (1.2%), and other subtypes
(5.7%).
By comparing old Mphy with new Mphy, the overall concordance was 97.7%
between the two approaches, with a subtyping agreement of 99.8% and 88.2% for B
and non-B subtypes, respectively. The 297 (2.3%) discrepant sequences reassigned as
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different subtypes were due to newly available CRF reference sequences in the HIV
sequence databases. Of note, new Mphy allowed the identiﬁcation of more CRFs than
old Mphy. The most prevalent reclassiﬁed subtypes, earlier assigned by old Mphy, were
F1 (n  52 [17.5%], 50 of them reclassiﬁed as BF recombinants), CRF02_AG (n  43
[14.5%], 41 of them reclassiﬁed as more complex recombinants), and B (n 41 [13.8%],
29 of them reclassiﬁed as BF recombinants) (Table 1).
Concordance between automated subtyping tools and new Mphy. HIV-1 sub-
types deﬁned by new Mphy were compared with those provided by the four rapid
subtyping tools (COMET, SCUEAL, REGA-v3, and Stanford [Stanford-old and Stanford-
v8.1]). Overall, the tool most concordant with new Mphy was Stanford-v8.1 (95.4%),
followed by COMET (93.8%), REGA-v3 (92.5%), Stanford-old (91.1%), and SCUEAL
(85.9%), as shown in Fig. 1A.
In particular, concordance with new Mphy was excellent for subtype B with all tools
(both Stanford versions, 99.8%; COMET, 99.3%; REGA-v3, 98.8%; and SCUEAL, 98.1%)
but was lower for non-B subtypes (Stanford-v8.1, 84.0%; COMET, 78.5%; REGA-v3,
74.9%; Stanford-old, 67.0%; and SCUEAL, 52.6%) (Fig. 1B and C). Thus, for both B and
non-B subtypes, the highest concordance rates were reported with Stanford-v8.1.
Sensitivity and speciﬁcity of automated subtyping tools for HIV-1 pure sub-
types. Comparing new Mphy HIV-1 subtypes with those provided by the four rapid
subtyping tools, all the tools had a high sensitivity (98.0%) for subtype B (n  9,627)
(Table 2). In particular, the highest sensitivity was observed for Stanford-v8.1 (99.6%),
followed by COMET (99.5%), Stanford-old (99.0%), and SCUEAL and REGA-v3 (both
98.0%). The speciﬁcity of each tool was 97.9%, except for SCUEAL (95.7%) (Table 2).
TABLE 1 Reassigned HIV-1 subtypes using new Mphya
Old Mphy subtype/CRF (n) New Mphy subtype(s)/CRF(s) (n)
F1 (52) CRF71_BF (27), CRF72_BF (12), CRF40_BF (4), CRF70_BF (3), CRF05_DF (2), CRF12_BF (1), CRF39_BF (1),
CRF42_BF (1), CRF47_BF (1)
CRF02_AG (43) CRF36_cpx (18), CRF37_cpx (10), CRF06_cpx (8), CRF09_cpx (2), CRF01_AE (1), CRF20_BG (1), CRF25_cpx (1),
CRF43_02G (1), CRF63_02A1 (1)
B (41) CRF39_BF (9), CRF03_AB (4), CRF12_BF (4), CRF42_BF (4), CRF51_01B (4), CRF44_BF (3), CRF17_BF (2),
CRF28_BF (2), CRF38_BF (2), CRF08_BC (1), CRF15_01B (1), CRF23_BG (1), CRF40_BF (1), CRF46_BF (1),
CRF47_BF (1), D (1)
CRF12_BF (27) CRF05_DF (6), CRF40_BF (6), CRF72_BF (6), CRF29_BF (2), CRF42_BF (2), CRF03_AB (1), CRF28_BF (1),
CRF38_BF (1), CRF39_BF (1), CRF47_BF (1)
A1 (18) CRF22_01A1 (11), A2 (3), CRF35_AD (3), CRF02_AG (1)
CRF17_BF (14) CRF12_BF (5), CRF40_BF (3), CRF38_BF (2), CRF47_BF (2), CRF39_BF (1), CRF72_BF (1)
G (13) CRF43_02G (7), CRF02_AG (3), CRF06_cpx (1), CRF36_cpx (1), CRF32_06A1 (1)
CRF01_AE (12) F22_01A1 (11), CRF02_AG (1)
CRF28_BF (11) CRF29_BF (5), CRF40_BF (3), CRF12_BF (1), CRF42_BF (1), CRF60_BC (1)
aThe table reports subtypes obtained by using old Mphy and reclassiﬁed by new Mphy. Only reassigned subtypes with a prevalence of 3% are reported.
FIG 1 Concordance between HIV-1 automated subtyping tools and new Mphy in the overall population (A), for B subtype (B), and for non-B
subtypes (C).
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Considering subtype C (n  606), all the tools had a high sensitivity (91.9%) and
a high speciﬁcity (99.8%). For the other non-B pure subtypes (F1, F2, D, A1, and G),
Stanford-v8.1 showed the highest sensitivity for F1, F2, and D subtypes (99.1%, 100.0%,
and 97.4%, respectively) but not for A1 and G subtypes (81.8% and 59.8%, respectively),
which were better assigned by COMET (92.3%) and REGA-v3 (98.6%), respectively. Of
note, the speciﬁcity for these pure non-B subtypes was 99.1% for each tool (Table 2).
Sensitivity and speciﬁcity of automated subtyping tools for HIV-1 CRFs. The
Stanford-v8.1 tool had the best sensitivity in recognizing CRFs (Table 2). In particular,
the sensitivity was 92.9% on ﬁve different recombinants: CRF01_AE (98.0%),
CRF02_AG (98.5%), CRF06_cpx (95.4%), CRF11_cpx (92.9%), and CRF36_cpx (100.0%).
COMET also showed a desirable sensitivity on CRF02_AG (90.3%) and CRF01_AE
(92.9%). The speciﬁcity of each tool was 99.6% for all the CRFs (Table 2).
Performance of Stanford-v8.1 versus Stanford-old versions. To evaluate the
added value in subtyping performance of the new version of the Stanford tool
(Stanford-v8.1), potential subtype differences between the tool versions were evalu-
ated. Overall, concordance between Stanford-old versions and Stanford-v8.1 was
90.2%; in particular, the concordance was 99.0% and 66.2% on B and non-B subtypes,
respectively. In comparing the sensitivities of the different versions, Stanford-v8.1
signiﬁcantly improved the capacity in assigning subtypes B (from 99.0% to 99.6%, P 
0.0001), F1 (from 70.4% to 99.1%, P  0.0001), A1 (from 29.4% to 81.8%, P  0.0001),
and CRF02_AG (from 95.4% to 98.5%, P  0.0001). However, this capacity signiﬁcantly
decreased in assigning subtypes C (from 98.7% to 92.6%, P  0.0001) and G (from
93.0% to 59.8%, P  0.0001), which were wrongly classiﬁed as recombinant forms.
There were no signiﬁcant differences in sensitivity between the two tools for assigning
CRF01_AE (from 99.0% to 98.0%, P 1) (Table 2). Of note, as described in Materials and
Methods, the majority of CRFs are now more accurately identiﬁed by Stanford-v8.1 than
Stanford-old versions, due to the addition of CRF reference sequences in the Stanford
HIVdb.
Proposal for practical subtyping. Based on our results, we propose the following
algorithm for subtyping in routine clinical practice (Fig. 2). This strategy is based on the
desirable performance (90%) of automated subtyping tools with respect to new
Mphy. Brieﬂy, use Stanford-v8.1 as a screening tool for subtyping. If the output leads to
pure subtypes (B, C, D, or F) or CRFs (01_AE, 02_AG, 06_cpx, 11_cpx, or 36_cpx),
consider assigning the respective strain. If the output leads to subtype A1 or G, conﬁrm
with COMET or REGA-v3, respectively. If the output is different from the above, consider
performing Mphy for a subtype inference. If the output leads to all other non-B strains,
consider performing Mphy for a subtype inference (Fig. 2).
DISCUSSION
In this study, we aimed at assessing the necessity of updating MPhy, as well as the
current performance of commonly used automated subtyping tools, in an era of
changing molecular epidemiology in Western countries, including Italy (7, 12, 13, 15, 16,
28). Of note, the Italian clinical context is experiencing a rapid change in circulating
HIV-1 strains, mainly due to a diversiﬁed migration system, ongoing infection in the
high-risk populations (mostly men having sex with men [MSM]), and speciﬁc transmis-
sion clusters (12, 13). The large number of PR/reverse transcriptase (RT) sequence data
generated routinely from HIV-1-infected patients (n  13,116) and used for the present
assessment offers a greater representativeness of the present ﬁndings for settings with
closely related HIV epidemiological features. Of note, though subtype B remains highly
prevalent in our data set, there is a growing rate of non-B subtypes and recombinants,
thus conﬁrming the need for regular surveillance (7, 8, 12). Based on updated phylog-
eny (up to 79 CRFs at the moment), the 2.3% overall discordance reported from old
Mphy highlights the importance of continuously updating Mphy algorithms for an
accurate surveillance of newly emerging strains in countries sharing similar challenges
as Italy as well as in countries where non-B strains are predominant (6, 13, 15, 24, 25,
31). The high discrepancy observed with non-B subtypes (11.8% versus only 0.2% with
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B) underscores the need for greater considerations of non-B surveillance (7, 8, 12, 13).
This discrepancy observed between old Mphy and new Mphy highlights the need for
periodic updating of reference sequences for phylogenetic analyses (23, 24). In partic-
ular, new Mphy included 530 new reference sequences with respect to old Mphy, of
which 25.3% belonged to CRFs, and this could explain the 2.3% overall discordance
between old Mphy and new Mphy.
HIV-1 subtypes deﬁned by new Mphy were compared with those provided by the
four rapid subtyping tools (COMET, SCUEAL, REGA, and Stanford). These tools have
different characteristics in inferring subtypes (26). In particular, because REGA-v3 and
SCUEAL are phylogenetics-based tools, their computation times are longer than those
of other tools that are based on a statistical (COMET) or similarity (Stanford HIVdb)
approach (24, 26, 28, 29).
The overall concordance between automated subtyping tools and new Mphy
reveals an acceptable performance of all tools (90%), except for SCUEAL (85.9%). This
ﬁnding highlights the limited performance of the current SCUEAL for subtype assign-
ment in the context of a growing HIV-1 molecular epidemic in Western countries
(24, 27).
Regarding B versus non-B subtype assignment, an excellent concordance with all
automated subtyping tools (98.1%, including SCUEAL) was reported for the B sub-
type. This observation conﬁrms the suitability in B subtyping, largely due to an initial
design of algorithms based on subtype B reference sequences (15, 32). In contrast to
the B subtype, none of the automated tools achieved the desirable concordance for
non-B subtypes (ranging from 84.0% with Stanford-v8.1 down to 52.6% with SCUEAL).
However, although phylogenetic analysis remains the gold standard for subtyping, our
ﬁndings highlight that HIVdb in its updated version (Stanford-v8.1) offers the highest
accuracy compared to the other routinely used subtyping tools, for both B and non-B
FIG 2 Flow chart of a practical HIV-1 subtyping approach. This ﬂow chart represents the HIV-1 subtyping practical approach through online
subtyping tools, proposed in the case that Mphy cannot be used in routine practice due to its complexity.
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subtypes, thus serving as a convenient approach for subtype screening. The higher
number of CRF reference sequences used by Stanford-v8.1 for subtyping and thus the
better representation of the CRF circulation worldwide may explain the higher accuracy
in subtyping of this tool with respect to the others. Interestingly, all the CRF reference
sequences used by Stanford-v8.1 are included in our Mphy analysis, thus explaining the
high concordance between these two methodologies and conﬁrming Stanford-v8.1 as
the best tool for subtype assignment.
Moreover, these ﬁndings conﬁrm that regular updating improves sensitivity in
assigning HIV-1 strains, in an era of ongoing recombination events. This is in contrast
with our preliminary analyses conducted on about one-third of sequences and before
the release of the new version of Stanford HIVdb (30) and with other previous reports
on the performance of several subtyping tools (24, 26, 28), which is normal because our
analysis was performed on recently updated tools and with more reference sequences.
A high sensitivity for subtype B assignment (98.0%) was reported with all tools.
This is in accordance with previous ﬁndings and underlines the consistent reliability for
subtype B surveillance using current automated tools (24, 26, 28). Though the sensi-
tivities on subtype B were highly similar for all automated tools, SCUEAL showed the
lowest speciﬁcity (95.7%) by wrongly assigning some CRFs to subtype B. The current
overestimation of subtype B suggests caution when assigning this viral strain with
SCUEAL, thus giving preference for B subtyping to the other algorithms (Stanford HIVdb,
COMET, and REGA-v3).
Regarding subtype C, the excellent and similar sensitivities and speciﬁcities reported
for all the automatic subtyping tools indicate the suitability of all tools in discriminating
subtype C viruses (24, 33) and their possible routine use in settings with subtype C
predominance like southern Africa, eastern Africa, India, Nepal, and part of China (2, 5,
34). On one hand, Stanford-v8.1 showed excellent performance in sensitivity (97.4% to
100%) on other pure subtypes (D, F1, and F2) in contrast to other rapid tools (reporting
90% sensitivity); this indicates that Stanford-v8.1 might be acceptable in assigning D
or F strains. On the other hand, only COMET or REGA-v3 might be acceptable in
assigning viruses as subtype A1 or G, respectively (27, 29). Regarding the sensitivity to
recombinant forms, Stanford-v8.1 appeared highly reliable in assigning CRF01_AE,
CRF02_AG, CRF06_cpx, CRF11_cpx, and CRF36_cpx. COMET showed an acceptable
(though lower than Stanford-v8.1) performance only on CRF01_AE and CRF02_AG.
Thus, Stanford-v8.1 possesses the most reliable algorithm on major CRFs compared
with the other evaluated rapid tools. As this trend is consistent even with other CRFs
below target performance, the revolutionary update in Stanford-v8.1 now makes this
tool the reference automated subtyping tool, coupled with its wide use in clinical
practice. As described in Materials and Methods, the majority of CRFs are now more
accurately identiﬁed by Stanford-v8.1 than by older Stanford versions, due to the
addition of CRF reference sequences in HIVdb. Thus, the signiﬁcant improvements in
Stanford-v8.1 underscore the relevance of regular updating of both automated tools
and advanced phylogenetic approaches (23, 27, 28). In spite of its great performance,
Stanford-v8.1 has some limitations: misclassiﬁcation of CRFs 01_AE, 14_BG, 15_01B, and
46_BF (due to the absence of recombination breakpoints in the pol region), which are
subtypes A, G, AE, and F in the pol region, respectively (26). Moreover, Stanford-v8.1
wrongly classiﬁes 40.0% of G subtype strains as CRF43_02G (90.7%), CRF02_AG (7.0%),
or CRF06_cpx (2.3%) and 16.7% of A subtype strains as CRF01_AE (61.8%), CRF22_01A1
(19.1%), CRF09_cpx (8.5%), or CRF02_AG (10.6%), important considerations for those
areas where non-B strains are prevalent.
Through an evidence-based approach, we propose an algorithm that could be used
to facilitate the subtyping process during routine clinical practice. Such a subtyping
strategy becomes more relevant for settings where a large number of sequences are
routinely generated, with less expertise in advanced phylogeny, and limited resources
(Fig. 2).
There are some limitations observed with this study. First, we used pol sequences for
subtyping (35), instead of the full genome, which could provide a better assignment.
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This could be a problem especially for those CRFs with recombination breakpoints
outside the pol region, as reported above.
However, it should be considered that pol is the most extensively investigated
region for clinical and diagnostic purposes, and the more suitable way to assign a
correct subtype/CRF is to trim the pol sequences from full-length genomes of pure
subtypes and CRFs from the HIV sequence database, as previously reported by Pineda-
Peña et al. (26).
Moreover, the underrepresentativeness of some non-B strains (though with a higher
number than previous reports) warrants further investigations in those settings. Finally,
only the most commonly used rapid tools were included in the present analysis, thus
missing possible revisions of other existing tools.
In conclusion, Mphy remains the gold standard method for an accurate HIV-1
subtyping. In the case that Mphy cannot be used in routine practice due to its
complexity, online subtyping tools can be a valid option for the subtype characteriza-
tion. Though rapid subtyping tools have various performances with respect to Mphy,
Stanford-v8.1 appears most reliable for rapid subtyping of both pure and recombinant
strains. Thus, for practical use in routine clinical practice, the usage of Stanford-v8.1,
occasionally combined with COMET or REGA-v3, represents an effective subtyping
approach in clinical settings.
Periodic updating of algorithms together with the latest HIV-1 reference sequences
is fundamental to improve HIV-1 subtype characterization in the context of effective
epidemiological surveillance of non-B HIV-1 strains.
MATERIALS AND METHODS
Study population. The present study was conducted on a data set of 13,116 HIV-1 pol sequences
(containing the full-length protease [PR] and the ﬁrst 300/335 reverse transcriptase [RT] codons), performed
for routine clinical purposes from 1997 to 2015 in three reference laboratories in Italy (National Institute for
Infectious Diseases L. Spallanzani, IRCCS, Rome; University of Rome Tor Vergata, Rome; andModena University
Hospital, Modena) and in one in Cameroon (Chantal Biya International Reference for Research on HIV/AIDS
Prevention and Management, Yaoundé) and then collected in an anonymous database. HIV-1 pol genotype
analyses were performed on plasma samples, as previously described (36–38).
Mphy analysis. For each sequence, HIV-1 subtype was determined by molecular phylogeny (Mphy).
In particular, pol sequences were aligned by using Clustal X, with full-length reference sequences of HIV-1
subtypes and CRFs retrieved from the HIV sequence databases, available at https://www.hiv.lanl.gov/
content/sequence/NEWALIGN/align.html, using at least 10 reference sequences for each subtype/CRF, for
a total of 3,923 sequences. The alignment type chosen was the “all complete sequences” in the fasta
format, and only one sequence per patient was included. Then, the complete alignment was manually
trimmed from full-length genomes to the PR/RT region, and gaps were removed from the ﬁnal
alignment, by using BioEdit software version 7.2.5.
Two different Mphy analyses were conducted. (i) The ﬁrst Mphy (referred to as old Mphy) was
conducted with a data set of reference sequences available until 2014; (ii) the second one (referred to as
new Mphy) was performed with a data set of reference sequences updated in 2015, to evaluate possible
discrepancies with previous subtype assignments. In particular, in the 2015 analysis we had 530 more
reference sequences than those available in the 2014 analysis. Subtype or CRF assignments were
achieved by constructing phylogenetic trees using the neighbor-joining (NJ) method (39). Regarding old
Mphy, until 2009, the F84 substitution model with both NJ and maximum likelihood (ML) tree building
methods was used (40), performed by PAUP software (http://paup.sc.fsu.edu/). From 2010 until now,
phylogenetic analyses were conducted using MEGA (version 5, from 2010 to 2013; version 6, from 2014
until now), based on the Kimura 2-parameter (K2P) model (41). The reliability of the branching orders was
assessed by bootstrap analysis of 1,000 replicates. To conﬁrm subtype classiﬁcation, an ML tree with
1,000 bootstrap replicates, a general time-reversible (GTR) nucleotide substitution model with gamma
distribution among site heterogeneity, and a proportion of invariable sites (GI) were inferred. A
sequence that clustered monophyletically inside a clade with a bootstrap support value of 70% was
assigned to that clade; otherwise, the sequence was analyzed for recombination using RDP4 software.
Recombination events detected are displayed graphically, with statistical evidence provided, and recom-
bination events are also drawn on phylogenetic trees constructed from proposed recombinant regions.
For the sequences without any signal for recombination, the sequence was assigned the clade with the
highest similarity in RDP4 with a bootstrap support value of 70%; differently, in the presence of a
recombination signal, the sequence was identiﬁed as a unique recombinant form (URF) (Fig. 3) (26, 42).
The trees were rooted using midpoint rooting by FigTree software version 1.4.2 (http://tree.bio.ed.ac
.uk/software/ﬁgtree/).
HIV-1 automated subtyping assignment. The entire pol sequence data set was analyzed using
four automatic tools: COMET (https://comet.lih.lu/), REGA-v3 (http://dbpartners.stanford.edu:8080/
RegaSubtyping/stanford-hiv/typingtool/), SCUEAL (http://www.datamonkey.org/dataupload_scueal.php),
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and Stanford HIVdb (versions 1.0 to 7.0, referred to as Stanford-old, or Stanford HIVdb 8.1 version,
referred to as Stanford-v8.1). Regarding Stanford HIVdb, until 14 September 2016, the only reference
sequences present in Stanford-old were the pure subtypes A, B, C, D, F, and G and the two CRFs
01_AE and 02_AG. The Stanford algorithm has now been updated, with the addition of HIV-1 group
M reference sequences for CRFs up to 65. In addition to the current update in Stanford HIVdb, the
pol gene is now concatenated to encompass the entire PR/RT/IN sequence. Features of the updated
reference sequences in Stanford-v8.1, used in the present subtyping assessment, are now available
in the open-source project for subtyping (https://github.com/hivdb/hiv-genotyper/blob/master/src/
main/resources/HIVGenotypeReferences.json).
Concordance, sensitivity, and speciﬁcity. Since new Mphy was considered the gold standard, the
performance of automated tools versus new Mphy was evaluated in terms of subtyping agreement
(concordance), sensitivity, and speciﬁcity. When the automated tool reported the same HIV-1 subtype/
CRF as the new Mphy did, the result was considered concordant. Regarding Stanford HIVdb, because old
versions separated PR and RT subtype results, different results between PR and RT were considered
discordant. Sensitivity and speciﬁcity were calculated using the formula available at http://statpages
.info/ctab2x2.html. Desirable target performance was set at 90%.
Statistical analysis. Statistical signiﬁcance of the differences between subtyping tools was evaluated
with McNemar’s test, using R version 3.3.1; P values of 0.05 were considered statistically signiﬁcant.
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